Back to top

Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session

Read MoreHide Full Article

Immunomedics, Inc. (IMMU - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 36.4% in the past one-month time frame.

The move came after the company reported that it had entered into an alliance with Boulder, CO-based Clovis Oncology.

The company has seen a mixed track record when it comes to estimate revisions of one increase and one decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarterremained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

A better-ranked stock in the Medical - Biomedical and Genetics industry is Genomic Health, Inc. (GHDX - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is IMMU going up? Or down? Predict to see what others think: Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Genomic Health, Inc. (GHDX) - free report >>

Immunomedics, Inc. (IMMU) - free report >>

More from Zacks Tale of the Tape

You May Like